Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Opening Session Panel Discussion

Apr

Today In Oncology

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Opening Session Panel Discussion

Use of Statins in CLL/SLL

High-Fiber Diet May Slow Disease Progression to Multiple Myeloma

Omission of Endocrine Therapy in Estrogen Receptor-Low Early-Stage Breast Cancer

Childhood Exposure to Bacterial Toxin May Trigger Early Onset Colorectal Cancer

WHI Funding Future Unclear